Dynavax Technologies Corporation reaffirmed financial guidance for the full year 2024. For the year, the company expects HEPLISAV-B net product revenue between approximately $265 million - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.32 USD | +2.75% | +8.17% | -11.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.87% | 1.61B | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.31% | 22.48B | |
-9.56% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024